Sizzling Buy-Rated Biotechs Highlight 5 Top Stocks Under $10

Harpoon Therapeutic

Aggressive biotech investors should probably take a look at this company. Harpoon Therapeutics Inc. (NASDAQ: HARP) is a clinical-stage immunotherapy company engaged in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.

The company’s lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase 1/2a clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase 1/2a clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217, which is in Phase 1/2 clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase 1/2 clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors.

Harpoon Therapeutic has a discovery collaboration and license agreement with AbbVie Biotechnology to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors.

Citigroup recently upgraded the shares and has a $16 price target. The consensus target is much higher at $28.10. The stock closed trading on Friday at $6.92.

MarketWise

This stock has been cut in half since going public back in late July. MarketWise Inc. (NASDAQ: MKTW) operates a multibrand platform of subscription businesses that provides financial research, software, education and tools for investors.

MarketWise provides a portfolio of independent investment research, as well as various software and analytical tools on a subscription basis. The company offers its research across various platforms, including desktop and laptop, as well as mobile devices, such as tablets and cell phones.

With more than 20 years of operating history, MarketWise is currently composed of 12 primary customer-facing brands, offering more than 160 products, and serving a community of 13 million free and paid subscribers. The company’s products are a trusted source for high-value financial research, education, actionable investment ideas and investment software. MarketWise is a 100% digital, direct-to-customer company offering its research across a variety of platforms including mobile, desktops and tablets.

Needham began coverage of the stock last month, and it has a $13 price target. The consensus target is up at $15, and the stock was last seen on Friday at $7.08.

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.